الفهرس 
Anatomy of the LiverOnly 14 pages are availabe for public view
 |  | from | 349 |  |  |
| | | from | 349 | | |
Abstract
Hepatocellular carcinoma (HCC) is considered to be one of the most common malignancies worldwide, In Egypt a high incidence rate of HCC has been reported with a strong association between chronic HCV infection, cirrhosis and HCC Therefore, given the facts of the high incidence of HCC in cirrhosis together with the poor prognosis in late diagnosis, therapeutic strategies in HCC should incorporate concepts for early detection and screening in individuals at risk.
Treatment of HCC is based on: transplantation, resection, ablation, and embolization.
Transplantation remains the treatment of choice for patients with early HCC offering cure for both malignancy and cirrhosis. However, limited organ availability and rapid tumor advance narrowed this treatment options for most patients with HCC and hence the need for a bridge therapy until transplantation.
Unfortunately, the vast majority of patients with HCC are not suitable for any of the surgical treatment options. Thus, various treatments other than surgical resection have been investigated for potential palliation or even cure of unresectable hepatic tumours. Examples of such treatments include systemic or infusional chemotherapy, hepatic artery ligation or embolization, percutaneous ethanol injection (PEI) cryosurgery, radiofrequency ablation (RFA), chemoembolization, and radiolabeled antibodies, often in conjunction with surgical resection and/or radiation therapy.
In the last few years combined techniques were introduced successfully as new adjuvant therapy for the unresectable HCC or bridging therapy for patients waiting transplantation.
TACE and RFA are the best combinations till now aiming to use both techniques combined to gain most of their benefits in ablation of the HCC controlling its size, local and distant progression without affection of the proper hepatic reserve for already compromised cirrhotic patients.